Treatment of genital herpes simplex virus infection with photodynamic inactivation.
A double-blind randomized study to evaluate the effect of proflavine in the treatment of genital herpesvirus infection was conducted. One hundred fifty-seven women were studied, of whom 75 were treated with proflavine (treated women) and 82 were treated with placebo (control group). There were 62 women with primary disease and 95 with recurrent infection. Under the conditions by which this study was conducted, there was no apparent difference in the time of healing of lesions, development of recurrences, or virus isolation following treatment in the proflavine-treated and control groups.
D000166:Acridines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006561:Herpes Simplex / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D010789:Phototherapy; D010919:Placebos; D011370:Proflavine / Q000627:therapeutic use*; D012008:Recurrence; D018139:Simplexvirus / Q000302:isolation & purification; D013997:Time Factors; D002577:Uterine Cervical Diseases / Q000188:drug therapy / Q000628:therapy*; D014845:Vulvar Diseases / Q000188:drug therapy / Q000628:therapy*
D000166:Acridines; D010919:Placebos; D011370:Proflavine